Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celyad Oncology SA

CYAD.BR ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Belgium Micro Cap Analyst: HOLD

Last Close

$0.28

▲ +0.42%

Market Cap $13.06M · Vol 33.51K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

18.03

FWD: N/A

Market Cap

$13.06M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

44.12

Momentum

Beta

0.94

vs Market

52W High

$0.75

64.29% below

52W Low

$0.18

46.40% above

Volume

33.51K

Avg 13.85K

P/B

3.12

Price-to-book

ROE

N/A

Return on equity

Free Float

34.30%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Celyad Oncology SA (CYAD.BR) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CYAD.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.31%

-13.62%

-10.41%

-22.51%

YTD

+41.76%

-19.67%

-66.64%

-93.51%

Financials & Valuation

TTM · Annual

Total Revenue	$24.66K
Net Income	$974.83K
Revenue Growth (YoY)	-95.93%
Gross Margin	61.90%
Operating Margin	-13,928.57%
Net Profit Margin	3,952.38%
ROE	N/A
ROA · ROIC	11.67% · N/A

P/E Ratio	18.03
Forward P/E (FY1)	N/A
PEG Ratio	0.08
P/S	346.32
P/B	3.12
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	47.26M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.31
RSI (14)	44.12
Beta	0.94
52-Week High	$0.75
52-Week Low	$0.18

Volume Today	33.51K
Avg Daily Volume (30D)	13.85K
Relative Volume	2.42x
Volatility (10D)	120.98
Volatility (30D)	87.15
Free Float	34.30%

Analyst Consensus

HOLD

Current Price $0.28

Mean Target N/A

52W Low$0.18 52W High$0.75

Current

Target

$0.18 $0.75

Current Analyst target

· 0 analysts

Identifiers

ExchangeEurope

FIGIBBG001T539K9

ISINBE0974260896

CountryBelgium

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).